Skip to main content

Table 1 Patient demographics and HAE treatment characteristics

From: Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy

  N = 14
Age, mean (range) 47.5 (28–72)
Gender, female, n (%) 9 (64.3)
Race, n (%)  
 White 13 (92.9)
 Black 1 (7.1)
Time since HAE diagnosis, years, mean (range) 31 (6–61)
Employment status, n (%)  
 Full time 8 (57.1)
 Part time 2 (14.3)
 Retired 2 (14.3)
 Full-time parent 1 (7.1)
 Unemployed due to HAE 1 (7.1)
Comorbidities (self-reported), n (%)  
 None 6 (40.0)
 Allergic rhinitis/conjunctivitis or seasonal allergies 5 (33.3)
 Hypertension 4 (26.7)
 Anxiety 3 (20.0)
 Depression 2 (13.3)
 Asthma 2 (13.3)
 GERD 1 (6.7)
 Anemia 1 (6.7)
 Hypothyroidism 1 (6.7)
 Positive ANA nucleolar 1:640 1 (6.7)
Prior HAE prophylaxis  
 Plasma-derived C1INH(IV) 9 (64.3)
 Androgens 2a (14.3)
 No long-term prophylaxis 2 (14.3)
 Unknown 1 (7.1)
Current on-demand treatment, n (%)  
 Icatibant only 9 (64.3)
 Icatibant and plasma-derived C1INH(IV) 2 (14.3)
 Icatibant and recombinant C1INH(IV) 1 (7.1)
 Plasma-derived C1INH(IV) only 1 (7.1)
 Recombinant C1INH(IV) only 1 (7.1)
  1. The above reflects information gathered at the time of interview
  2. C1INH(IV) intravenous C1 esterase inhibitor, GERD gastroesophageal reflux disease, HAE hereditary angioedema
  3. a1-stanozolol, 1-danazol